



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

**Video Editor**  
Luis Chiva (Spain)

**Social Media Editors**  
Andreina Fernandes (Venezuela)  
Aarthi S. Jayraj (United Kingdom)

**Managing Editor**  
Emily Hammond (USA)

**Editorial Office**  
International Journal of Gynecological Cancer, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jgeditorial.com](mailto:ijgc@jgeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [bmj.com/company/products/services/rights-and-licensing/](http://bmj.com/company/products/services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2023 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead Article

- 649** ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023\*  
 OPEN ACCESS  
*D Cibula, M R Raspollini, F Planchamp, C Centeno, C Chargari, A Felix, D Fischerová, D Jahnn-Kuch, F Joly, C Kohler, S Lax, D Lorusso, U Mahantshetty, P Mathevet, R Naik, R A Nout, A Oaknin, F Peccatori, J Persson, D Querleu, S R Bernabé, M P Schmid, A Stepanyan, V Svintsitskiy, K Tamussino, I Zapardiel, J Lindegaard*


## Editorial

- 667** ESGO/ESTRO/ESP updated guidelines in cervical cancer  
*P T Ramirez*

## Cervical Cancer


- 669** Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women  
*L C Snyman, K L Richter, A Lukhwareni, G Dreyer, M H Botha, F H Van Der Merwe, C Visser, G Dreyer*

- 676** PET-MRI and evaluation of response to radiochemotherapy in patients with locally advanced cervical cancer  
*A Weyl, C Chollet, E Gabiache, V Cancès-Lauwers, F Gallo, A Martinez, F Courbon, P Laguevaque, I Brenot Rossi, A Jalaguier, E Lambaudie, E Chantalat, S Motton*


- 683** Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix  
 OPEN ACCESS  
*S Peleg Hasson, S Felder, L Helpman, A Taylor, M Shalamov, S Abuakar, S Bauer, R Shapira-Frommer, I Greenhouse, J Korach, T Rabin, J Goldstein, A Saad*

- 692** Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311)  
*M Ishikawa, T Shibata, T Kataoka, M Takekuma, H Kobayashi, N Yaegashi, T Satoh, on behalf of the Gynecologic Cancer Study Group in Japan Clinical Oncology Group*

## Uterine Cancer

- 701** Uterine smooth muscle tumors with uncertain malignant potential: analysis following fertility-saving procedures  
 OPEN ACCESS  
*A Richtarova, B Boudova, P Dunder, Z Lisa, K Hlinecka, Z Zizka, F Fruhauf, D Kuzel, J Slama, M Mara*
- 707** Human chorionic gonadotropin expression in endometrial hyperplasia and endometrial carcinoma: could it be a new marker?  
*M Daggez, M Dolanbay, H Akgun, V Gülsüren, S A Keklikcioglu, B Ozcelik, I S Serin*

- 713** Effect of BMI change on recurrence risk in patients with endometrial cancer  
*I Laskov, A Zilberman, L Maltz-Yacobi, S Peleg Hasson, A Cohen, T Safra, D Grisaru, N Michaan*

- 719** Multi-institutional study on the role of post-operative radiotherapy in elderly patients with endometrial cancer  
 EDITOR'S CHOICE  
*G Yavas, O C Guler, M Gultekin, E Oymak, S Yuce Sari, F Yildiz, C Onal*

## Ovarian Cancer

- 727** Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction  
*A Mohammad, C Ainio, D M Narasimhulu, M McGree, A L Weaver, A Kumar, A Garbi, A Mariani, G Aletti, F Multinu, C Langstraat, W Cliby*

- 734** Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence  
*H Plett, E Ricciardi, V Vacaru, J P Ramspott, N Colombo, J Sehoul, A du Bois, A Garbi, R Richter, B Ataseven, G Aletti, E Braicu, F Heitz, R Portuesi, M-Z Muallem, T Dagues, G Parma, E Roser, A Traut, F Multinu, P Harter*

- 741** Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome  
*D Huang, R Harrison, E Curtis, N Mirabadi, G Y Chen, R Alexandridis, L Barroilhet, S Rose, E Hartenbach, A Al-Niami*

- 749** Secondary validation of an ovarian cancer-specific comorbidity index in a US population

*C Vranes, H Zhao, M C Noer, S Fu, C C Sun, R Harrison, P T Ramirez, C K Høgdall, S H Giordano, L A Meyer*

- 755** Impact of lymphadenectomy and intra-operative tumor rupture on survival in early-stage mucinous ovarian cancers

*S R Kim, A Madariaga, L Hogen, D Vicus, A Covens, C Parra-Herran, S Lheureux, L T Gien*

## Surgery

- 761** Can the Tilburg Frailty Indicator predict post-operative quality of recovery in patients with gynecologic cancer? A prospective cohort study

*C Liu, W Gao, W Meng, M Ding, R Huang, Y Xiao, L Zhou, S Wang, X Wei*

## Survivorship

- 770** Black and hispanic women have less support during cancer evaluation and treatment: results from a prospective patient reported outcomes program in gynecologic malignancy

*L Philp, S Alimena, M Sullivan, M Del Carmen, A Bregar, E Eisenhauer, A Goodman, R C Sisodia*

- 778** Assessing gaps in motherhood after cancer: development and psychometric testing of the Survivorship Oncofertility Barriers Scale

*A Hoffman, C J Denham, S Fu, T Mendoza, R Nitecki, K A Jorgensen, J Garcia, K Lamiman, T L Woodard, J A Rauh-Hain*

## Pain Management

- 786** Opioid and benzodiazepine use in gynecologic oncology patients

*K Levvitska, S R Pena, J Brown, Z Yu, M K Wally, J R Hsu, R B Seymour, W Naumann, PRIMUM Group*

## Integrative Medicine

- 792** Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study

*E Ben-Arye, D Gamus, N Samuels, E Schiff, D Hausner, O Gressel, S Attias, O Lavie, A David, K Shulman, A Aghbarya*

## Reviews

- 802** Quality assurance in human papillomavirus testing for primary cervical screening



*K Cuschieri, M D Fellner, L S Arroyo Mühr, E Padalko, R M Correa, J Dillner, M Gultekin, M A Picconi*

- 812** PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy



*A Chelariu-Raicu, F Trillsch, A Burges, B Czogalla, A Hester, R Wuerstlein, N Harbeck, S Mahner*

## Clinical trial

- 823** Improving Endometrial cancer assessment by combining the new technique of GENomic profiling with surgical Extra uterine disEase assessment (EUGENIE)

*J C Kasius, R Trozzi, J Pijnenborg, T Baert, A Laenen, A-S Van Rompuy, I Zapardiel, G Vizzielli, J Knez, F Fanfani, F Amant*

## Tumor board

- 827** Recurrent leiomyomatosis peritonealis disseminata

*E Sanchez Diaz, G J Rendon Pereira, R Pareja, O G Palacios Rodriguez, C A Serna Ortíz, C P Huertas Duran*

## Corners of the world

- 833** The "06" committee: an untiring soldier in the Tunisian fight against gynecologic cancer

*M Ghalleb, L Naija, I Zemni, M Slimane, M Hechiche*

## Video articles

- 835** Transumbilical laparoendoscopic single-site radical trachelectomy with uterine arteries' ascending branches preservation for early-stage cervical cancer



*Y Chen, Y Zheng, Q Wang, S Dai*

- 837** Visual dilation and curettage for the fertility-sparing treatment of atypical endometrial hyperplasia/endometrial intra-epithelial neoplasia: an easy to perform in-office technique

*P Casadio, A Raffone, P Salucci, D Raimondo, R Seracchioli, J Carugno, A Di Spiezio Sardo*

- 839** Aggressive angiomyxoma of the pelvis and vagina: a robotic and vaginal combined approach

*A Luzarraga Aznar, A Perez-Benavente, V Bebia, N R Gómez-Hidalgo, S Cabrera, A Gil-Moreno*

---

### Educational video lecture

- 841** Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications

*R Pareja*

---

### Pathology archives

- 843** Ovarian clear cell carcinoma: an overview of key histopathologic features

*H Taylor, D Costigan*

- 845** Ganglioglioma arising in an ovarian teratoma

*A Santoro, N D'Alessandris, G Scaglione, G F Zannoni*

---

### Images

- 848** Rare presentation of endometrial cancer with uterine inversion

*R Hablase, N Das, K Lutchman Singh*

---

### Commentaries

- 849** Can we improve survival with less overall morbidity for patients with intermediate-risk cervical cancer without the use of external beam radiotherapy?

*C Chargari, R A Nout, J Lindegaard, P Morice*

- 851** The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer

*D J Brennan, W J van Driel, O Zivanovic*